Cargando…
Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective Analysis
BACKGROUND: A significant percentage of lung adenocarcinomas have a driver mutation. To date, there has been no assessment of the prevalence of such mutations in a Middle Eastern population. The present multicenter prospective study of formalin fixed paraffin embedded (FFPE) tissues from patients di...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5563085/ https://www.ncbi.nlm.nih.gov/pubmed/28240017 http://dx.doi.org/10.22034/APJCP.2017.18.1.107 |
_version_ | 1783258071802314752 |
---|---|
author | Tfayli, Arafat Rafei, Hind Mina, Alain Khalil, Maya Fakhreddin, Najla Mahfouz, Rami Hamouri, Shadi Farhat, Fadi Salem, Ziad Dbouk, Haifa Rabee, Haider Saghir, Nagi Shamseddine, Ali Makarem, Jawad Bitar, Nizar Mougharbil, Anas Assi, Hazem Temraz, Sally Mukherji, Deborah Matalka, Ismail Zaatari, Ghazi |
author_facet | Tfayli, Arafat Rafei, Hind Mina, Alain Khalil, Maya Fakhreddin, Najla Mahfouz, Rami Hamouri, Shadi Farhat, Fadi Salem, Ziad Dbouk, Haifa Rabee, Haider Saghir, Nagi Shamseddine, Ali Makarem, Jawad Bitar, Nizar Mougharbil, Anas Assi, Hazem Temraz, Sally Mukherji, Deborah Matalka, Ismail Zaatari, Ghazi |
author_sort | Tfayli, Arafat |
collection | PubMed |
description | BACKGROUND: A significant percentage of lung adenocarcinomas have a driver mutation. To date, there has been no assessment of the prevalence of such mutations in a Middle Eastern population. The present multicenter prospective study of formalin fixed paraffin embedded (FFPE) tissues from patients diagnosed with lung adenocarcinoma was performed to assess the prevalence of EGFR and ALK mutations in the Levant. METHODS: Patients of Middle Eastern origin with lung adenocarcinomas at 10 sites in Lebanon, Jordan and Iraq were prospectively enrolled. Tumors were tested for EGFR by PCR and for EML4-ALK translocation by fluorescence in situ hybridization (FISH). RESULTS: A total of 210 patients were enrolled, 139 (66.2%) males and 71 females (33.8%), with a mean age of 63.4 years. EGFR testing of 205 (97.6%) demonstrated the wild type in 173 (84.4%) and mutated forms in 32 (15.6%). Some 46.9% of EGFR positive patients were non-smokers and 62.5% were females as opposed to 22.4% and 33.8%, respectively, in the general population. As for the EML4-ALK translocation, testing in 157 (74.8%) cases gave negative results in 154 (98.1%), only 3 being positive (1.9%), 2 being females and 2 non-smokers. CONCLUSION: Our study established a 15.6% EGFR mutation rate in lung adenocarcinomas with ALK translocation mutations in only 1.9%, as compared to a 15-20% and 5%, respectively, in the Western literature. |
format | Online Article Text |
id | pubmed-5563085 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | West Asia Organization for Cancer Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-55630852017-08-28 Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective Analysis Tfayli, Arafat Rafei, Hind Mina, Alain Khalil, Maya Fakhreddin, Najla Mahfouz, Rami Hamouri, Shadi Farhat, Fadi Salem, Ziad Dbouk, Haifa Rabee, Haider Saghir, Nagi Shamseddine, Ali Makarem, Jawad Bitar, Nizar Mougharbil, Anas Assi, Hazem Temraz, Sally Mukherji, Deborah Matalka, Ismail Zaatari, Ghazi Asian Pac J Cancer Prev Research Article BACKGROUND: A significant percentage of lung adenocarcinomas have a driver mutation. To date, there has been no assessment of the prevalence of such mutations in a Middle Eastern population. The present multicenter prospective study of formalin fixed paraffin embedded (FFPE) tissues from patients diagnosed with lung adenocarcinoma was performed to assess the prevalence of EGFR and ALK mutations in the Levant. METHODS: Patients of Middle Eastern origin with lung adenocarcinomas at 10 sites in Lebanon, Jordan and Iraq were prospectively enrolled. Tumors were tested for EGFR by PCR and for EML4-ALK translocation by fluorescence in situ hybridization (FISH). RESULTS: A total of 210 patients were enrolled, 139 (66.2%) males and 71 females (33.8%), with a mean age of 63.4 years. EGFR testing of 205 (97.6%) demonstrated the wild type in 173 (84.4%) and mutated forms in 32 (15.6%). Some 46.9% of EGFR positive patients were non-smokers and 62.5% were females as opposed to 22.4% and 33.8%, respectively, in the general population. As for the EML4-ALK translocation, testing in 157 (74.8%) cases gave negative results in 154 (98.1%), only 3 being positive (1.9%), 2 being females and 2 non-smokers. CONCLUSION: Our study established a 15.6% EGFR mutation rate in lung adenocarcinomas with ALK translocation mutations in only 1.9%, as compared to a 15-20% and 5%, respectively, in the Western literature. West Asia Organization for Cancer Prevention 2017 /pmc/articles/PMC5563085/ /pubmed/28240017 http://dx.doi.org/10.22034/APJCP.2017.18.1.107 Text en Copyright: © Asian Pacific Journal of Cancer Prevention http://creativecommons.org/licenses/BY-SA/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License |
spellingShingle | Research Article Tfayli, Arafat Rafei, Hind Mina, Alain Khalil, Maya Fakhreddin, Najla Mahfouz, Rami Hamouri, Shadi Farhat, Fadi Salem, Ziad Dbouk, Haifa Rabee, Haider Saghir, Nagi Shamseddine, Ali Makarem, Jawad Bitar, Nizar Mougharbil, Anas Assi, Hazem Temraz, Sally Mukherji, Deborah Matalka, Ismail Zaatari, Ghazi Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective Analysis |
title | Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective Analysis |
title_full | Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective Analysis |
title_fullStr | Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective Analysis |
title_full_unstemmed | Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective Analysis |
title_short | Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective Analysis |
title_sort | prevalence of egfr and alk mutations in lung adenocarcinomas in the levant area - a prospective analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5563085/ https://www.ncbi.nlm.nih.gov/pubmed/28240017 http://dx.doi.org/10.22034/APJCP.2017.18.1.107 |
work_keys_str_mv | AT tfayliarafat prevalenceofegfrandalkmutationsinlungadenocarcinomasinthelevantareaaprospectiveanalysis AT rafeihind prevalenceofegfrandalkmutationsinlungadenocarcinomasinthelevantareaaprospectiveanalysis AT minaalain prevalenceofegfrandalkmutationsinlungadenocarcinomasinthelevantareaaprospectiveanalysis AT khalilmaya prevalenceofegfrandalkmutationsinlungadenocarcinomasinthelevantareaaprospectiveanalysis AT fakhreddinnajla prevalenceofegfrandalkmutationsinlungadenocarcinomasinthelevantareaaprospectiveanalysis AT mahfouzrami prevalenceofegfrandalkmutationsinlungadenocarcinomasinthelevantareaaprospectiveanalysis AT hamourishadi prevalenceofegfrandalkmutationsinlungadenocarcinomasinthelevantareaaprospectiveanalysis AT farhatfadi prevalenceofegfrandalkmutationsinlungadenocarcinomasinthelevantareaaprospectiveanalysis AT salemziad prevalenceofegfrandalkmutationsinlungadenocarcinomasinthelevantareaaprospectiveanalysis AT dboukhaifa prevalenceofegfrandalkmutationsinlungadenocarcinomasinthelevantareaaprospectiveanalysis AT rabeehaider prevalenceofegfrandalkmutationsinlungadenocarcinomasinthelevantareaaprospectiveanalysis AT saghirnagi prevalenceofegfrandalkmutationsinlungadenocarcinomasinthelevantareaaprospectiveanalysis AT shamseddineali prevalenceofegfrandalkmutationsinlungadenocarcinomasinthelevantareaaprospectiveanalysis AT makaremjawad prevalenceofegfrandalkmutationsinlungadenocarcinomasinthelevantareaaprospectiveanalysis AT bitarnizar prevalenceofegfrandalkmutationsinlungadenocarcinomasinthelevantareaaprospectiveanalysis AT mougharbilanas prevalenceofegfrandalkmutationsinlungadenocarcinomasinthelevantareaaprospectiveanalysis AT assihazem prevalenceofegfrandalkmutationsinlungadenocarcinomasinthelevantareaaprospectiveanalysis AT temrazsally prevalenceofegfrandalkmutationsinlungadenocarcinomasinthelevantareaaprospectiveanalysis AT mukherjideborah prevalenceofegfrandalkmutationsinlungadenocarcinomasinthelevantareaaprospectiveanalysis AT matalkaismail prevalenceofegfrandalkmutationsinlungadenocarcinomasinthelevantareaaprospectiveanalysis AT zaatarighazi prevalenceofegfrandalkmutationsinlungadenocarcinomasinthelevantareaaprospectiveanalysis |